ANNEMARIE TREVISANI LABELLA: Open Payments
NPI 1710137765 · UTICA, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,940 in 79 payments from 18 companies in 2025. Trend: 2023 $1,167 · 2024 $1,757 · 2025 $1,940
Food & beverage: $1,940
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 29 | $688 |
| Madrigal Pharmaceuticals | 5 | $294 |
| Janssen Biotech, Inc. | 5 | $109 |
| GENZYME CORPORATION | 4 | $102 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 6 | $97 |
| Gilead Sciences, Inc. | 4 | $89 |
| Regeneron Healthcare Solutions, Inc. | 3 | $87 |
| Intercept Pharmaceuticals, Inc. | 4 | $82 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $69 |
| Lilly USA, LLC | 3 | $63 |
Products named: RINVOQ, REZDIFFRA, SKYRIZI, DUPIXENT, CREON, TREMFYA, XIFAXAN, OCALIVA.
Industry payments across NY — which companies pay providers there.
